Diabetes

The pair of studies evaluating the technology were presented at the American Diabetes Association and simultaneously published in the Journal of Diabetes Science and Technology.

Reseachers are studying whether drugs that have been approved for treating type 2 diabetes can be used in combination with insulin to avoid both variablity in blood glucose and weight gain.

A packed session greeted the highly anticipated results of the LEADER trial, which found that the GLP-1 receptor agonist liraglutide has cardiovascular benefits in high-risk patients with diabetes.

Data from CDC consistently show that low-income, minority groups are at higher risk for diabetes, for genetic but especially for environmental reasons.

Evidence presented Sunday at the 76th Scientific Sessions of the American Diabetes Association comes as competition is heating up over a pair of therapies that combine insulin with a GLP-1 receptor agonist.

Vitamin D may help reduce the risk of diabetes side effects associated with atypical antipsychotics, according to a recent study published in Scientific Reports.

Poster presentations at the American Diabetes Association Scientific Sessions compared canagliflozin, an SGLT2 inhibitor, to sitagliptin, a popular DPP-4 inhibitor, using claims data.

Intarcia Therapeutics anticipates filing for FDA approval at the end of the third quarter of 2016. At this year's ADA presentation, Julio Rosenstock, MD, said the insertion method for the novel therapy delivery device continues to improve.

In an ADA session called "Follow the Money," panelists led by Joslin Diabetes Center's Robert A. Gabbay, MD, PhD, FACP, discussed the diabetes cost burden, insulin costs, and payment models.

Speakers at the 76th Scientific Sessions of the American Diabetes Association discussed current donor transplant successes and engineering challenges of efforts to generate islet cells in the laboratory.

This week in managed care, the top stories included discussions on biomarkers and financial toxicity at the annual meeting of the American Society of Clinical Oncology, and a preview of the 76th Scientific Sessions of the American Diabetes Association.

A poster at an ADA session on barriers and facilitators to novel care found that top concerns of patients with diabetes often have nothing to do with the disease. Other studies looked at which comorbidities contribute the most to readmissions or length of stay, and how an intervention that focused on transitions of care reduced A1C in patients with uncontrolled diabetes.

Robert M. Anderson, EdD, of the University of Michigan, has spent his career spreading a message that patients respond best when education programs address what they want, not what an expert thinks they need.

A commentary in the special issue of JAMA on obesity argues that the nation has reached a point where therapy can no longer undo the damage of poor diets and lack of exercise, and a reckoning of policy change is needed.

Older patients and those with other complications are at greatest risk.

This year at The American Journal of Managed Care's 4th annual Patient-Centered Diabetes Care meeting, select faculty provided their key takeaways from the sessions.

The first study sheds light on the complex interaction between underlying metabolic risk and breast cancer.

A secondary analysis of data from the TECOS trial of sitagliptin finds that the drug does not affect the risk for heart failure hospitalization or related adverse clinical outcomes in people with type 2 diabetes

Cardiovascular outcomes trials, new technologies, and the fight over what we eat will be featured at the upcoming 76th Scientific Sessions of the American Diabetes Association in New Orleans.

Recent coverage of our research, in both the healthcare and mainstream press.

The study highlights results from the population largely denied CGM coverage under Medicare.

Interim results from the ongoing CANVAS (Canagliflozin Cardiovascular Assessment Study) clinical trial have found an increased risk of leg and foot amputations associated with the popular diabetes medication.

The proposal calls for 2-year and 10-year goals to gradually reduce Americans' salt intake. This strategy has been used in the past when it became clear that FDA would seek ways to limit sugar consumption.

Guidelines and an article in the issue take on the thorny question of how obese type 2 patients must be for surgery to be effective in improving glycemic control.

Part 1: See Part 2 in the September issue of Evidence-Based Diabetes Management.